title: Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
abstract: The study aims at establishing a novel vaccine procedure, using bone marrow-derived DCs that have ingested apoptotic B16 melanoma (DCs(+)), alone or in combination with splenic T lymphocytes from a syngenic donor. Co-immunization with DCs(+) and T cells showed the highest antitumor potential against preestablished B16 tumor in mice, in which CTL and NK cytotoxicities were drastically elevated, while either DCs(+) alone, naive DCs (DCs(-)) alone, or a mixture of DCs(-) and T cells induced less significant therapeutic outcomes. Use of extracellular matrix proteins elevated antitumor activity of DC(-)/T cell vaccine. Compared with the CD8(+) cells, the CD4(+)T cells more remarkably improved the efficacy of DC-based immunotherapy. The present system may be a feasible therapeutic modality to eradicate malignancies including melanoma.
authors.affiliation: Department of Biotechnology, Faculty of Engineering, Kyoto Sangyo University, Kyoto 603-8555, Japan.
authors.forename: Hidetsugu
authors.initials: H
authors.lastname: Asada
authors.forename: Tsunao
authors.initials: T
authors.lastname: Kishida
authors.forename: Hideyo
authors.initials: H
authors.lastname: Hirai
authors.forename: Masaharu
authors.initials: M
authors.lastname: Shin-Ya
authors.forename: Jiro
authors.initials: J
authors.lastname: Imanishi
authors.forename: Minoru
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Osam
authors.initials: O
authors.lastname: Mazda
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D000964:Antimetabolites, Antineoplastic; D017209:Apoptosis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D016326:Extracellular Matrix Proteins / Q000276:immunology; D005260:Female; D016219:Immunotherapy, Adoptive / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D011691:Puromycin; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014185:Transplantation, Isogeneic
chemical_list: D000951:Antigens, Neoplasm; D000964:Antimetabolites, Antineoplastic; D019496:Cancer Vaccines; D016326:Extracellular Matrix Proteins; D011691:Puromycin